QWhat is the mechanism of action of deucravacitinib?

A
Richard Winkelmann, DO

Richard Winkelmann, DO

Director for Dermatology and Mohs Surgery
Optum Care
Los Angeles, CA

Deucravacitinib is an oral medication with selective inhibition of tyrosine kinase 2 (TYK2). It binds to the inactive pseudokinase regulatory domain of TYK2 stabilizing its interaction between regulatory and catalytic domains. TYK2 mediates multiple cytokine pathways including IL-23 which in turn impacts the production of IL-17. Deucravacitinib is FDA approved for treatment in adults with moderate to severe plaque psoriasis.

References:

  1. SM Hoy. Drugs, 2022.
  2. SOTYKTU [package insert]. Bristol-Myers Squibb Company, 2022.